Fresenius Medical Care launches multiFiltratePRO system in the U.S. after FDA clearance
Fresenius Medical Care launched the multiFiltratePRO system in the United States after receiving FDA clearance on October 19, 2026. The clearance includes the Cienby and Calrezdy solutions, which allow regional citrate anticoagulation as indicated. According to the text, this is an initial U.S. commercialization step that expands the company's critical care portfolio, following the recent U.S. introduction of the 5008X.
In 30 seconds
- Fresenius Medical Care launched the multiFiltratePRO system in the U.S. with FDA clearance dated October 19, 2026.
- The clearance includes the Cienby and Calrezdy solutions for regional citrate anticoagulation.
- The company expands its critical care portfolio after the recent U.S. introduction of the 5008X.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.